Adverse Prognostic Significance of Activation-Induced Cytidine Deaminase in Diffuse Large B-Cell Lymphoma Patients Treated With R-CHOP
AID protein expression may explain why some lymphoma patients respond differently to standard chemotherapy, potentially improving how we predict treatment outcomes.
This retrospective study of 70 Indonesian DLBCL patients finds that AID expression is a significant adverse prognostic factor specifically in patients receiving rituximab-based therapy (R-CHOP), with a hazard ratio of 10.39, suggesting AID may modulate R-CHOP efficacy through immune escape mechanisms. This rituximab-specific interaction has implications for DLBCL risk stratification and warrants validation in larger prospective cohorts.
What the study was
- Study design
- Retrospective cohort study
- Population
- DLBCL patients in Indonesia treated with CHOP ± rituximab
- Sample size
- 70
- Category
- Diagnostics
- Maturity
- Exploratory
- Journal
- Cancer Reports (Hoboken)
Why it surfaced
Retrospective, single-institution, small N=70; rituximab-specific AID prognostic finding is clinically interesting but needs prospective validation; Indonesian cohort may not generalize.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.